Medical Xpress November 12, 2024
Researchers led by Osaka University in Japan have conducted the first human trial using induced pluripotent stem-cell-derived corneal epithelium to treat limbal stem cell deficiency, offering a potential new avenue for restoring vision.
Limbal stem cell deficiency (LSCD) is a severe ocular condition where the loss of functioning adult stem cells at the cornea’s edge leads to vision impairment due to the invasion of fibrotic conjunctival tissue over the cornea. Limbal stem cells normally perform repair functions by differentiating into corneal epithelium. Without them, the integrity and transparency of the corneal surface becomes compromised, leading to fibrotic tissue buildup, and ultimately, vision loss.
Traditional treatments often involve grafts from the patient’s healthy eye or donors, but these methods carry risks...
Today's Sponsors
Today's Sponsor